Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05811169

Quest for Tumour Evolution of Non-small Cell Lung Cancer

Quest for Tumour Evolution of Non-small Cell Lung Cancer in Chinese (Unicorn-Quest)

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
The University of Hong Kong · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

To study and comprehend the evolutionary and genomic landscape between primary and metastatic sites and the dynamics of intratumour and intertumour heterogeneity over time with reference to the treatment modalities for each Chinese patient with non-small cell lung cancer.

Detailed description

The importance of intratumour and intertumour heterogeneity in non-small cell lung cancer has been extensively interrogated recently. However there is a lack of similar data associated with treatment and survival outcomes in Chinese population. Unicorn-Quest, a prospective observational study of Chinese patients with either primary or metastatic non-small cell lung cancer, aims to identify the evolutionary changes from the primary tumour, regional nodes and distant metastases of the same patients and among different patients, through multiregion and longitudinal tumour and nodal collection with next-generation sequencing. By following non-small cell lung cancer from early stage to relapse or distant metastasis, identifying the changes of genomic landscape with correlation with treatment and survival outcomes, this study may help identify unique cancer trajectories and novel therapeutic targets for non-small cell lung cancer in Chinese population.

Conditions

Interventions

TypeNameDescription
GENETICNext generation sequencingNext generation sequencing

Timeline

Start date
2023-02-15
Primary completion
2025-12-31
Completion
2026-12-31
First posted
2023-04-13
Last updated
2023-04-13

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT05811169. Inclusion in this directory is not an endorsement.